サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：統合失調症治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 製品タイプ別、流通チャネル別、地域別
市場調査レポート
商品コード
1410585

統合失調症治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 製品タイプ別、流通チャネル別、地域別

Schizophrenia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 185 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
統合失調症治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 製品タイプ別、流通チャネル別、地域別
出版日: 2024年01月10日
発行: Fairfield Market Research
ページ情報: 英文 185 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

統合失調症は、現実に対する異常な解釈を特徴とし、幻覚や妄想を含む様々な行動の変化を引き起こします。統合失調症の治療は継続的なものとなり、薬物療法は脳内のドーパミンレベルを調節することによって患者の行動をコントロールする上で極めて重要な役割を果たしています。

抗精神病薬、特に第二世代抗精神病薬は、第一世代抗精神病薬に比べて副作用が少ないため、一般的に処方されています。薬物療法に加え、個別療法や社会技能療法などの治療も行われ、統合失調症患者の生活の質を高めています。

世界保健機関（WHO）によると、世界で約5,000万人が統合失調症に罹患しています。有病率は低下しているもの、この疾患の診断率や処方率は上昇を続けており、統合失調症治療薬の大幅な成長が見込まれています。

診断率の増加は、治療を求める患者数の増加に起因しています。1970年に統合失調症に対する最初の非定型抗精神病薬が導入されて以来、非定型抗精神病薬に関連する副作用の軽減により、治療の追求は著しく増加しています。

統合失調症治療薬市場の主要企業は、機会を捉えるために積極的に商業化提携や研究提携を結んでいます。共同研究や提携はM&Aよりも効果的であり、即座に好影響をもたらすことが証明されています。統合失調症治療薬のメーカーもまた、新興市場を収益創出の道として模索しています。

当レポートでは、世界の統合失調症治療市場について調査し、市場の概要とともに、製品タイプ別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の統合失調症治療市場の見通し、2018年～2031年

  • 世界の統合失調症治療市場の見通し、製品タイプ別、金額（100万米ドル）、2018年～2031年
  • 世界の統合失調症治療市場の見通し、流通チャネル別、金額（100万米ドル）、2018年～2031年
  • 世界の統合失調症治療市場の見通し、地域別、金額（100万米ドル）、2018年～2031年

第4章 北米の統合失調症治療市場の見通し、2018年～2031年

第5章 欧州の統合失調症治療市場の見通し、2018年～2031年

第6章 アジア太平洋の統合失調症治療市場の見通し、2018年～2031年

第7章 ラテンアメリカの統合失調症治療市場の見通し、2018年～2031年

第8章 中東・アフリカの統合失調症治療市場の見通し、2018年～2031年

第9章 競合情勢

  • メーカーと流通チャネル別のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競争力ダッシュボード
  • 企業プロファイル
    • Johnson & Johnson Services, Inc.
    • Bristol-Myers Squibb Company
    • Otsuka Holdings Co., Ltd
    • AstraZeneca
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Eli Lilly and Company
    • Alkermes
    • Vanda Pharmaceuticals
    • ALLERGAN
    • Pfizer Inc.

第10章 付録

目次

Schizophrenia, a chronic disorder that profoundly impacts individuals' lives, is characterized by an abnormal interpretation of reality and leads to various behavioral changes, including hallucinations and delusions. Schizophrenia treatment is an ongoing journey, with medications playing a pivotal role in controlling patients' behavior by regulating dopamine levels in the brain.

Advancements in Treatment

Antipsychotic medications, particularly second-generation antipsychotics, are commonly prescribed due to their reduced side effects compared to first-generation counterparts. In addition to medication, schizophrenia is also addressed through therapies such as individual therapy and social skill therapy, enhancing the quality of life for individuals living with schizophrenia.

Global Market Insights

A comprehensive research report on the global schizophrenia treatment market explores various therapies and their market scenarios across different regions. The report delves into trends, drivers, challenges, and opportunities shaping the landscape. According to the research, the global schizophrenia treatment market is poised for robust expansion in the coming years.

The Burden of Schizophrenia

According to the World Health Organization, approximately 50 million people worldwide are affected by schizophrenia. Despite a declining prevalence rate, the diagnosis and prescription rates for this disorder continue to rise, creating substantial growth prospects for schizophrenia treatment.

The increasing rate of diagnosis can be attributed to a growing number of patients seeking treatment. Since the introduction of the first atypical antipsychotic treatment for schizophrenia in 1970, the pursuit of treatment has significantly increased, thanks to the reduced side effects associated with atypical psychotic medications.

Collaborative Efforts Drive Market Growth

Key players in the schizophrenia treatment market are actively forging commercialization and research alliances to seize opportunities. Collaborations and partnerships have proven to be more effective than mergers and acquisitions, yielding immediate positive impacts. Manufacturers of schizophrenia medications are also exploring emerging markets as avenues for revenue generation.

Atypical Antipsychotics Take the Lead

Among the various medications available for schizophrenia, atypical antipsychotic treatment, a second-generation medication, stands out for its effectiveness and fewer side effects. The atypical antipsychotics segment is projected to experience high growth during the forecast period.

Miscellaneous antipsychotic agents, including lithium, pimozide, molindone, haloperidol, and loxapine, are also gaining traction. Physicians often opt for haloperidol and lithium due to their effectiveness and competitive pricing. The miscellaneous antipsychotic agents segment is expected to expand at a value CAGR of 6.1% throughout the assessment period.

As the global schizophrenia treatment market continues to evolve, it holds the promise of transforming the lives of individuals affected by this challenging disorder. The focus on innovative treatments and collaborative efforts reflects the commitment of stakeholders to improve the well-being and outlook for those living with schizophrenia.

Schizophrenia Treatment Market Segmentation:

By Product Type

  • Atypical Antipsychotics
  • Phenothiazine Antipsychotics
  • Thioxanthenes
  • Miscellaneous Antipsychotic Agents

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce

By Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan (APEJ)
  • Japan
  • Middle East and Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Schizophrenia Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Schizophrenia Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Atypical Antipsychotics
      • 3.1.1.2. Phenothiazine Antipsychotics
      • 3.1.1.3. Thioxanthenes
      • 3.1.1.4. Miscellaneous Antipsychotic Agents
  • 3.2. Global Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospital Pharmacies
      • 3.2.1.2. Drug Stores
      • 3.2.1.3. Retail Pharmacies
      • 3.2.1.4. E-Commerce
  • 3.3. Global Schizophrenia Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Schizophrenia Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Atypical Antipsychotics
      • 4.1.1.2. Phenothiazine Antipsychotics
      • 4.1.1.3. Thioxanthenes
      • 4.1.1.4. Miscellaneous Antipsychotic Agents
  • 4.2. North America Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospital Pharmacies
      • 4.2.1.2. Drug Stores
      • 4.2.1.3. Retail Pharmacies
      • 4.2.1.4. E-Commerce
    • 4.2.2. BPS Analysis/Market Attractiveness Analysis
  • 4.3. North America Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 4.3.1.2. U.S. Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 4.3.1.3. Canada Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 4.3.1.4. Canada Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Schizophrenia Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Atypical Antipsychotics
      • 5.1.1.2. Phenothiazine Antipsychotics
      • 5.1.1.3. Thioxanthenes
      • 5.1.1.4. Miscellaneous Antipsychotic Agents
  • 5.2. Europe Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospital Pharmacies
      • 5.2.1.2. Drug Stores
      • 5.2.1.3. Retail Pharmacies
      • 5.2.1.4. E-Commerce
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.2. Germany Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.3. U.K. Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.4. U.K. Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.5. France Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.6. France Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.7. Italy Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.8. Italy Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.9. Turkey Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.10. Turkey Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.11. Russia Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.12. Russia Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Schizophrenia Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Atypical Antipsychotics
      • 6.1.1.2. Phenothiazine Antipsychotics
      • 6.1.1.3. Thioxanthenes
      • 6.1.1.4. Miscellaneous Antipsychotic Agents
  • 6.2. Asia Pacific Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospital Pharmacies
      • 6.2.1.2. Drug Stores
      • 6.2.1.3. Retail Pharmacies
      • 6.2.1.4. E-Commerce
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 6.3.1.2. China Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.3. Japan Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 6.3.1.4. Japan Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.5. South Korea Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 6.3.1.6. South Korea Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.7. India Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 6.3.1.8. India Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Schizophrenia Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Atypical Antipsychotics
      • 7.1.1.2. Phenothiazine Antipsychotics
      • 7.1.1.3. Thioxanthenes
      • 7.1.1.4. Miscellaneous Antipsychotic Agents
  • 7.2. Latin America Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Hospital Pharmacies
      • 7.2.1.2. Drug Stores
      • 7.2.1.3. Retail Pharmacies
      • 7.2.1.4. E-Commerce
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 7.3.1.2. Brazil Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.3.1.3. Mexico Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 7.3.1.4. Mexico Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.3.1.5. Argentina Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 7.3.1.6. Argentina Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Schizophrenia Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Atypical Antipsychotics
      • 8.1.1.2. Phenothiazine Antipsychotics
      • 8.1.1.3. Thioxanthenes
      • 8.1.1.4. Miscellaneous Antipsychotic Agents
  • 8.2. Middle East & Africa Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospital Pharmacies
      • 8.2.1.2. Drug Stores
      • 8.2.1.3. Retail Pharmacies
      • 8.2.1.4. E-Commerce
  • 8.3. Middle East & Africa Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 8.3.1.2. GCC Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.3.1.3. South Africa Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 8.3.1.4. South Africa Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.3.1.5. Egypt Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 8.3.1.6. Egypt Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.3.1.7. Nigeria Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 8.3.1.8. Nigeria Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Manufacturer vs by Distribution Channel Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Johnson & Johnson Services, Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Bristol-Myers Squibb Company
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Otsuka Holdings Co., Ltd
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. AstraZeneca
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Sumitomo Dainippon Pharma Co., Ltd.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Eli Lilly and Company
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Alkermes
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Vanda Pharmaceuticals
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. ALLERGAN
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Pfizer Inc.
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations